Author:
Diab Khaled,Zaidan Mohamed F.,Samir Sameh,Derballa Obaida A.,Aboelnor Mahmoud I.,Habashy Hany F.
Abstract
Background/aim
A crucial approach for finding breast cancer sooner is the triple examination of breast diseases. Our goal was to determine if ultrasound-guided core biopsies were required to investigate clinically ambiguous breast tumors that lacked imaging features suspicious for malignancy in Breast Imaging Reporting and Data System 3.
Patients and methods
A prospective study was performed on 50 patients fulfilling our eligibility criteria who presented with symptomatic indeterminate breast masses chosen according to our selection criteria and underwent an ultrasonography-guided core biopsy in the period from January 2021 to March 2022.
Results
A total of 50 clinically ambiguous breast masses were investigated, of which 47 (94%) were benign lesions, including 34 (68%) lesions were fibroadenomas, six (12%) lesions were fibrocystic disorder without ductal hyperplasia, one (2%) lesion was fibrocystic disease with ductal hyperplasia with no atypia, and six (12%) lesions showed periductal mastitis. Two (4%) lesions were proliferative breast lesions with focal atypia. One (2%) lesion was infiltrating duct carcinoma grade 2.
Conclusion
Ultrasound-guided core biopsy is necessary for investigating clinically indeterminate breast mass in symptomatic patients with Breast Imaging Reporting and Data System 3 finding on imaging, for early detection of malignancy and atypical hyperplastic changes.
Reference17 articles.
1. Understanding breast cancer as a global health concern;Wilkinson;Br J Radiol,2022
2. Ultrasound as a complement to mammography and breast examination to characterize breast masses;Taylor;Ultrasound Med Biol,2002
3. Triple test in carcinoma breast;Kharkwal;J Clin Diagn Res,2014
4. Cancer incidence in Egypt: results of the national population-based cancer registry program;Ibrahim;J Cancer Epidemiol,2014
5. Pattern of presentation of patients with breast cancer in Iraq in 2018: a cross-sectional study;Mutar;J Glob Oncol,2019